CRISPR Therapeutics
CRSP
CRISPR Therapeutics (CRSP) earnings history
Most recent quarter
- Fiscal period
- Q3 2025
- Period end
- Sep 30, 2025
- EPS actual
- −$1.17
- EPS estimate
- −$1.26
- EPS surprise
- +7.48%
- Revenue surprise
- −90.25%
- Revenue
- $889,000.00
- Revenue estimate
- $9.1M
- Reported
- Nov 10, 2025
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q3 2025 | Nov 10, 2025 | −$1.26 | −$1.17 | +7.48% | $889,000.00 | SEC |
| Q2 2025 | Aug 4, 2025 | −$1.40 | −$2.40 | −71.25% | $892,000.00 | SEC |
| Q1 2025 | May 6, 2025 | −$1.24 | −$1.58 | −27.05% | $865,000.00 | SEC |
| Q4 2024 | Feb 11, 2025 | −$1.20 | −$0.44 | +63.35% | $35.7M | SEC |
| Q3 2024 | Nov 5, 2024 | −$1.41 | −$1.01 | +28.29% | $602,000.00 | SEC |
| Q2 2024 | Aug 5, 2024 | −$1.43 | −$1.49 | −4.38% | $517,000.00 | SEC |
| Q1 2024 | May 8, 2024 | −$1.36 | −$1.43 | −5.09% | $504,000.00 | SEC |
| Q4 2023 | Feb 21, 2024 | $0.07 | $1.10 | +1559.13% | $201.2M | SEC |
| Q3 2023 | Nov 6, 2023 | −$1.99 | −$1.41 | +29.12% | $0.00 | SEC |
| Q2 2023 | Aug 7, 2023 | −$2.13 | −$0.98 | +53.93% | $70.0M | SEC |
| Q1 2023 | May 8, 2023 | −$1.74 | −$0.67 | +61.52% | $100.0M | SEC |
| Q4 2022 | Feb 21, 2023 | −$2.25 | −$1.41 | +37.34% | $6,000.00 | SEC |
| Q3 2022 | Nov 1, 2022 | −$2.28 | −$2.24 | +1.66% | $94,000.00 | SEC |
| Q2 2022 | Aug 8, 2022 | −$2.22 | −$2.40 | −8.27% | $158,000.00 | SEC |
| Q1 2022 | May 9, 2022 | −$1.94 | −$2.32 | −19.64% | $940,000.00 | SEC |
| Q4 2021 | Feb 15, 2022 | −$1.76 | −$1.84 | −4.30% | $12.9M | SEC |
| Q3 2021 | Nov 3, 2021 | −$1.75 | −$1.67 | +4.72% | $824,000.00 | SEC |
| Q2 2021 | Jul 29, 2021 | $3.52 | $9.44 | +167.99% | $900.7M | SEC |
| Q1 2021 | Apr 27, 2021 | −$1.47 | −$1.51 | −2.53% | $539,000.00 | SEC |
| Q4 2020 | Feb 16, 2021 | −$1.27 | −$1.50 | −17.82% | $370,000.00 | SEC |
Quarterly revenue
Frequently asked questions
When did CRISPR Therapeutics (CRSP) last report earnings?
CRISPR Therapeutics last reported on Nov 10, 2025, covering fiscal Q3 2025.
Did CRSP beat earnings estimates?
Yes. CRISPR Therapeutics reported EPS of −$1.17 for Q3 2025 against a −$1.26 estimate — a 7.48% beat.
How much revenue did CRSP report last quarter?
CRISPR Therapeutics reported $889,000.00 in revenue for Q3 2025, against a consensus estimate of $9.1M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.